VanEck Biotech ETF (NASDAQ:BBH) Short Interest Down 24.1% in February

VanEck Biotech ETF (NASDAQ:BBH) saw a significant drop in short interest in February. As of February 15th, there was short interest totalling 2,200 shares, a drop of 24.1% from the January 31st total of 2,900 shares. Based on an average trading volume of 11,700 shares, the short-interest ratio is presently 0.2 days.

VanEck Biotech ETF Stock Up 1.9 %

Shares of BBH opened at $165.50 on Thursday. The company has a market capitalization of $403.82 million, a P/E ratio of 30.97 and a beta of 0.85. The firm has a 50 day moving average of $161.75 and a 200 day moving average of $168.70. VanEck Biotech ETF has a twelve month low of $151.35 and a twelve month high of $183.64.

VanEck Biotech ETF Dividend Announcement

The business also recently announced a dividend, which was paid on Tuesday, December 24th. Shareholders of record on Monday, December 23rd were given a $1.2517 dividend. The ex-dividend date was Monday, December 23rd.

Institutional Investors Weigh In On VanEck Biotech ETF

Large investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC bought a new stake in VanEck Biotech ETF in the 4th quarter worth approximately $32,000. Truvestments Capital LLC bought a new stake in VanEck Biotech ETF in the 3rd quarter worth approximately $44,000. FSA Wealth Management LLC bought a new stake in VanEck Biotech ETF in the 3rd quarter worth approximately $54,000. Coastline Trust Co bought a new stake in VanEck Biotech ETF in the 3rd quarter worth approximately $59,000. Finally, SBI Securities Co. Ltd. bought a new stake in VanEck Biotech ETF in the 4th quarter worth approximately $81,000. Institutional investors own 32.05% of the company’s stock.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.